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Abstract
Background: Protective immunity to malaria is acquired after repeated infections in endemic areas. Asymptomatic
multiclonal P. falciparum infections are common and may predict host protection. Here, we have investigated the effect of
clearing asymptomatic infections on the risk of clinical malaria.
Methods: Malaria episodes were continuously monitored in 405 children (1–6 years) in an area of moderate transmission,
coastal Kenya. Blood samples collected on four occasions were assessed by genotyping the polymorphic P. falciparum
merozoite surface protein 2 using fluorescent PCR and capillary electrophoresis. Following the second survey, asymptomatic
infections were cleared with a full course of dihydroartemisinin.
Results: Children who were parasite negative by PCR had a lower risk of subsequent malaria regardless of whether
treatment had been given. Children with $2 clones had a reduced risk of febrile malaria compared with 1 clone after
clearance of asymptomatic infections, but not if asymptomatic infections were not cleared. Multiclonal infection was
associated with an increased risk of re-infection after drug treatment. However, among the children who were re-infected,
multiclonal infections were associated with a shift from clinical malaria to asymptomatic parasitaemia.
Conclusion: The number of clones was associated with exposure as well as blood stage immunity. These effects were
distinguished by clearing asymptomatic infection with anti-malarials. Exposure to multiple P. falciparum infections is
associated with protective immunity, but there appears to be an additional effect in untreated multiclonal infections that
offsets this protective effect.
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Introduction
Immune protection against Plasmodium falciparum malaria is
gradually acquired after repeated infections and largely dependent
on exposure intensity [1]. The severity and frequency of malaria
episodes decrease with age in areas of high transmission.
Nonetheless, parasites are often detected in the blood of
asymptomatic individuals and parasite prevalence is widely used
as a measure of transmission level [2]. Although, the mechanisms
by which protective malaria immunity is acquired and maintained
are still incompletely understood, antibodies are recognized to be
important [3]. Naturally acquired antibody responses to malaria in
younger children may, however, be rather short lived [4,5].
Although the persistence of asymptomatic parasitemia reflects the
non-sterilizing nature of malaria immunity, parasites may also be
important for the maintenance of immune responses [6] and
protection against new infections [7].
A characteristic of P. falciparum infections is the presence of
several genetically distinct parasite subpopulations, i.e. clones,
within a single individual. The number of infecting clones varies
with age [8,9] and transmission intensity [8,10,11,12]. Moreover,
asymptomatic multiclonal infections have been correlated with
varying risks of developing clinical malaria depending on the
transmission intensity. In high transmission settings and in older
children, a high diversity has been associated with a reduced risk of
subsequent clinical malaria [13,14]. In contrast, in areas of low
transmission and in younger children, a high number of clones are
associated with a higher risk [15,16,17].
To clarify the importance of persistent multiclonal P. falciparum
infections on host immunity, we have investigated how clearance
of asymptomatic infections affects the subsequent risk of clinical
malaria in children (1–6 years) living on the coast of Kenya. A
short acting anti-malarial drug (dihydroartemisinin) was given at
the beginning of the malaria transmission season [18]. The
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the highly polymorphic gene encoding the merozoite surface
protein 2 (msp2) using fluorescent PCR and capillary electropho-
resis [19]. The use of a short acting drug, with no or minor
prophylactic effect allowed for the specific assessment of clearance
of parasites without affecting exposure. Further, the heterogeneity
of exposure was addressed to distinguish the effect of protection
due to immunity from that of lack of exposure [20].
Materials and Methods
Study design
The study included samples collected during a randomized
controlled trial of a candidate malaria vaccine. The study and
extended follow up has been described in detail elsewhere [18,21].
Briefly, 405 children aged 1–6 years living in Junju sublocation in
Kilifi District, coastal Kenya were included. Malaria transmission
is moderate in Junju, with an estimated entomological inoculation
rate (EIR) of 22–53 in 1998 [22] and 19.8 infective bites per
person per year (CI 10.35–38.23) in 2010 (Janet Midega, personal
communication). Peak malaria transmission is associated with the
two rainy seasons in May to July and in November, but low level
transmission occurs all year. The five study villages can further be
divided into ‘‘high’’ (n=2) and ‘‘low’’ (n=3) transmission villages
based on previous surveillance of re-infection rates [23]. Written
consents were obtained from parents or guardians of participating
children. Ethical approval was obtained from Kenyan Medical
Research Institute National Ethics Committee, the Central
Oxford Research Ethics Committee, the London School of
Hygiene and Tropical Medicine Ethics Committee and from the
Regional Ethical Review Board in Stockholm, Sweden.
Clearing of asymptomatic infections and cross-sectional
blood samples
Scheduled venous blood samples were collected in EDTA at
initial screening in February 2005 and post-vaccination in May
2005. All children were then treated (independently of being
parasite positive or not) with direct observed dihydroartemisinin
monotherapy for seven days to clear asymptomatic parasiteamias,
beginning on the day of the blood sample taken in May. Parasite
clearance was confirmed by microscopical analysis of blood films
one week after ended treatment. Additional blood samples were
taken at cross-sectional surveys in August 2005 and January 2006
followed by an additional 9 months follow-up. To calculate
parasite density, the number of asexual-stage parasites per 200
leukocytes was counted by conventional light microscopy, and
parasiteamia was estimated on the basis of an assumed uniform
white cell count of 8000 leukocytes/ml blood. Hemoglobin (Hb)
levels were measured at all cross-sectional surveys.
Monitoring for clinical malaria
Clinical malaria was monitored weekly by home visits during
the total 18 months follow-up. Fieldworkers were resident in the
villages where children were recruited and readily accessible for
unscheduled visits if the children developed fever. When the
temperature was greater than 37.5uC, a blood film and a rapid
diagnostic test (OptiMALH, DiaMED) for malaria were conduct-
ed. The blood films were reviewed within 24–48 hours, but the
immediate treatment decisions were based on the rapid test result.
Clinical case definitions
Clinical malaria was defined as fever (axillary temperature
.37.5uC) and presence of .2500 P. falciparum parasites/ml. This
parasite threshold was set to increase the specificity of the endpoint
since asymptomatic parasiteamias are common among children in
this endemic area [24]. All clinical malaria episodes (independent
of parasite densities) were treated with artemether-lumefantrine
(CoArtemH) according to Kenyan national guidelines.
Msp2 genotyping of P. falciparum infection
Blood samples (n=1342) collected at the four cross-sectional
surveys were genotyped for msp2. Blood smear positive and negative
samples were included, so as to include submicroscopic infections.
DNAwasextractedusingABIPrism6100NucleicAcidPrepStation
(Applied Biosystems) (n=858) or PUREGENE
TM DNA Isolation
Kit (Gentra systems) (n=484). P. falciparum parasite populations
were characterized by msp2 genotyping using fluorescent PCR and
capillary electrophoresis (CE) as described previously [19]. Briefly,
the entire polymorphic region of msp2 (block 3) was amplified in a
primary reaction, followed by nested reactions where the respective
allelic types of msp2, FC27 and IC, were targeted with fluorescently
labeled primers in separate reactions. Fragment analysis was
performed in 96-well format in a 3130xl DNA sequencer and the
results were analyzed using GeneMapperH Software version 4.0
(both from Applied Biosystems). A 150 relative fluorescent unit (rfu)
cut off was set to distinguish true fragment peaks from background
fluorescence and other artefacts. Microscopy positive samples that
were negative by PCR were concentrated by ethanol precipitation
before repeating the PCR reaction.
Statistical methods
Analysis was performed using STATA (v10). Only strictly
asymptomatic children were included in the analysis, therefore all
children with a clinical episode at survey or in the period 28 days
before until 7 days after survey were excluded. Each child
contributed up to 4 separate periods of three months follow-up
after the respective cross-sectional bleeds.
Association between number of clones (no infection/1 clone/2
or more clones) and village of residence (high/low transmission),
age (years, continuous variable), Hb levels, vaccine i.e. malaria or
control (rabies vaccine) and insecticide treated bednet (ITN) use
(yes/no) were investigated by a Poisson model adjusted for
transmission season (dry/rainy) and corrected for repeated
observations per child by the robust cluster estimator. A single
multivariable model was produced. Correlation between parasite
density and age and number of clones was estimated using
Spearman rank correlation coefficient. This method was also used
to calculate the correlation of number of clones between surveys.
For survival analyses, data from the respective follow-up periods
was analyzed individually followed by pooled analysis for the
surveys without treatment (i.e. surveys 1, 3 and 4). The follow-up
after survey 2, with treatment, was analyzed separately. Cox
regression was used to assess the time to the first or only clinical
episode during follow-up (without/with treatment) in relation to
number of clones (0, 1 and $2). Hazard ratios (HR) were adjusted
for ITN use, age and village of residence (high/low transmission)
and transmission season i.e. dry/rainy (applicable only in the
pooled analysis). Schoenfeld residuals for non-proportionality were
analysed for each covariate. The linear fit of the model was tested
by examining multiple fractional polynomials and was not rejected
in favour of polynomial fits for age (P=0.38). MOI was fit in
categories (0 clones/1 clone/$2 clones).
In an analysis taking exposure into account, survey 2 was used
as baseline and the outcome during the three months follow-up
after parasite clearance was classified into three categories; (1)
clinical malaria (fever .37.5uC and .2500 P. falciparum parasites/
ml) during follow-up, (2) no clinical malaria but presence of
asymptomatic parasiteamia at the cross-sectional survey three
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clinical episode during follow-up nor any detectable parasites at
the following cross-sectional survey. Factors associated with the
different outcomes, i.e. number of clones, age, village of residence
(high/low transmission) and ITN use, were investigated by logistic
regression. When the outcome was re-infection (i.e. clinical
malaria or asymptomatic parasiteamia), the analysis was per-
formed excluding children who remained uninfected as these
children were considered less exposed.
Results
Out of the 405 children, msp2 genotyping data was available for
337, 360, 360 and 288 children from the four respective cross-
sectional surveys. Data records from 71 children were excluded due
to anti-malarial intake within 28 days before until 7 days after survey.
Vaccination had no effect on the incidence of clinical malaria
episodes or on prevalence of asymptomatic parasiteamias [18], nor
on number of clones measured in this study (P=0.9 by Student’s T).
The vaccine groups, i.e. malaria/control were therefore pooled for
further analysis.
Parasite prevalence and densities
At the first cross-sectional survey (Feb 2005), 263 (78%) children
were positive for P. falciparum by PCR. Parasite prevalence and
densities were lower at the next survey just before drug treatment
(May 2005) as well as after the two consecutive surveys three (Aug
2005) and nine months (Jan 2006) after treatment (Table 1). P.
falciparum infections were more often detected by PCR than by
microscopy at all time points, with an additional 5.9%–10.8%
being positive by PCR (Table 1). The prevalence of asymptomatic
infections increased with age (odds ratio OR=1.11 per year, 95%
confidence interval CI 1.07–1.16 by logistic regression) and was
associated with village of residence (OR=1.18 95% CI 1.03–1.33
by logistic regression in the high compared to the low transmission
villages). There was a linear correlation between parasite densities
and age (correlation coefficient, r=0.13 P,0.001).
Table 1. Parasitological characteristics at three-monthly cross-sectional surveys.
Before treatment After treatment
Survey 1 (Feb 2005) Survey 2 (May 2005) Survey 3 (Aug 2005) Survey 4 (Jan 2006)
Parasite prevalence, % (95% CI) microscopy 72.1 (67–77) 48.2 (43–53) 29.1 (24–34) 32.9 (27–38)
PCR 78.0 (74–83) 59.0 (53–64) 37.5 (32–43) 39.8 (34–45)
Parasite density
a, mean (95% CI) 708.0 (547.0–920.5) 223.9 (180.7–283.8) 112.2 (90.6–140.6) 120.2 (97.7–154.5)
aIn microscopy positive children.
Anti-malarial treatment was given to clear all asymptomatic parasiteamias just after survey 2.
doi:10.1371/journal.pone.0016940.t001
Figure 1. Number (A) and proportion (B) of asymptomatic children infected with different number of msp2 clones.
doi:10.1371/journal.pone.0016940.g001
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P. falciparum infections were mainly composed of $2 clones with
up to 8 clones at the most (Figure 1). The proportion of infections
with multiple clones was higher in the two first surveys (75% and
76%) than in the two last surveys after treatment was given (59.3%
and 59.1%), respectively. There was a high intra-individual
consistency in the number of clones between the surveys without
treatment. Individuals had a similar number of clones in these
consecutive pairs of surveys with a Spearman rank correlation
coefficient (r) of 0.39 (P,0.001) for survey 1 and 2, and r=0.53
(P,0.001) for survey 3 and 4, respectively (Figure 2, Table S1).
In contrast, the correlation was not as high when comparing
survey 2 and 3, (r=0.21, P,0.001) with an overall lower number
of clones in the survey after treatment (Figure 2, Table S1).
At all surveys, the number of clones was associated with age
(incidence risk ratio IRR=1.17, 95% CI 1.11–1.23 for each
year of age by Poisson regression P,0.0005), village of
residence (IRR=0.83, 95% CI 0.71–0.99 in the low transmis-
sion villages compared to the high transmission, P=0.032) and
Hb levels (IRR=0.9, 95% CI 0.87–0.94 per g/dl increase
P,0.0005), however not with ITN use (IRR=0.88, 95% CI
0.73–1.04, P=0.14). There was no systematic difference in the
results obtained with the two different DNA extraction methods
(data not shown). The number of clones was correlated with age
(Spearman non-parametric correlations r=0.21, P,0.001)
(Figure S1). Parasite densities were correlated with the number
of clones (Spearman non-parametric correlation coefficient
r=0.78, P,0.001). This correlation was non-linear indicating
that at high parasite densities, further increases in density are
no longer associated with increases in number of clones
(Figure S2).
Infection diversity and subsequent clinical malaria
In total 36, 13 and 12 clinical episodes with fever (.37.5uC) and
P. falciparum (.2500 parasites/ml) were reported in 337, 360 and
288 children in the follow-up periods without treatment (after
surveys 1, 3 and 4), while 59 episodes were reported in 360
children during the three months after treatment (after survey 2).
Age was associated with a decreased risk of clinical malaria both
without and with parasite clearance before follow-up (Table 2).
Children using ITN were at reduced risk after clearance (Table 2).
Anemia (hemoglobin level ,8 g/dl) was not associated with
subsequent risk of clinical malaria (HR=0.78, 95% CI 0.3–2.1,
P=0.7) after adjusting for MOI, village and age.
When time to the first or only clinical episode was assessed for
the respective follow-up periods, the number of clones was
significantly associated with disease risk only after treatment in
survey 2. There were fewer episodes in the surveys without drug-
treatment, but no statistical evidence of interactions between
survey number and village (P=0.28), ITN use (P=0.59), number
of clones (P=0.65) or age (P=0.07). Data from these different
follow-up periods without treatment (i.e. for survey 1, 3 and 4)
were therefore pooled.
Children who were parasite negative at the cross-sectional
surveys had a lower risk of subsequent malaria both in the follow-
up periods without and with treatment; HR 0.47 (95% CI 0.22–
0.98, P=0.045 by Cox regression) and HR 0.52 (95% CI 0.27–
0.99, P=0.045), respectively. The number of clones at the surveys
Figure 2. Intra-individual correlation in number of infecting clones between surveys without (A and C) and with treatment (B).
doi:10.1371/journal.pone.0016940.g002
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to one clone (HR=1.15 95% CI 0.60–2.19, P=0.68) (Figure 3).
However, children infected with $2 clones had a clearly reduced
risk in the period after clearance; HR 0.46 (95% CI 0.23–0.91,
P=0.026) (Figure 3).
The interaction term between the number of clones and the
effect of treatment on subsequent clinical malaria was analyzed in
a model using data from all follow-up periods (without and with
treatment). There was no significant interaction with the effect of 0
clones, HR=0.63 (95%CI 0.24–1.66, P=0.36 by Cox regression).
However, the interaction term was HR=3.54 (95%CI 1.4–9.1,
P=0.009) for the effect of $2 clones and the effect of treatment.
This confirms that the number of clones acts significantly
differently on the risk of clinical malaria depending on whether
not treatment was given after the survey.
In an analysis to distinguish the effects of lack of exposure from
protection due to an efficient immunity, outcomes after treatment
were analyzed in all children at the risk of re-infection (i.e. both
clinical malaria and asymptomatic) compared with those remain-
ing uninfected. In those re-infected, the risk of clinical malaria was
compared with asymptomatic infections. The risk of re-infection
when comparing 0 clones with 1 clone was not significantly
different, however $2 clones was associated with an increased risk
of re-infection with borderline significance (OR=1.97 95% CI
Table 2. Factors associated with risk of subsequent clinical malaria during follow-up with and without anti-malarial treatment after
survey.
No treatment after survey
a Treatment after survey
b
Hazard ratio (95% CI) P Hazard ratio (95% CI) P
msp2 clones 0 0.47 (0.22–0.98) 0.045 0.52 (0.27–0.99) 0.045
1* 1.0 1.0
$2 1.15 (0.60–2.19) 0.67 0.46 (0.23–0.91) 0.026
Age 0.81 (0.66–0.98) 0.027 0.76 (0.63–0.92) 0.006
High transmission 0.69 (0.41–1.18) 0.18 0.82 (0.48–1.41) 0.48
ITN 1.01 (0.58–1.77) 0.97 0.35 (0.17–0.75) 0.007
aPooled data from surveys 1, 3 and 4.
bData from survey 2.
*Reference group.
doi:10.1371/journal.pone.0016940.t002
Figure 3. Kaplan Meier estimate of time to subsequent clinical episode without and with treatment following survey.
doi:10.1371/journal.pone.0016940.g003
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was used as a continuous variable, the risk of re-infection
associated with clone number was OR=1.29 (95%CI 1.06–1.58,
P=0.013). In those re-infected, being parasite negative or infected
with $2 clones at survey 2 were both associated with a reduced
risk of clinical malaria compared with 1 clone (OR=0.19 95 CI
0.05–0.73 and OR=0.06 95% CI 0.02–0.25, respectively)
(Figure 4).
Discussion
Clearance of asymptomatic P. falciparum infections with one full
course of an effective anti-malarial drug affected the genetic
diversity of infections during follow-up and the subsequent risk of
clinical malaria. Without treatment, we did not observe any
significant effect of the number of clones on the risk of infection.
However, when the infections were cleared, children with 2 or
more clones just prior to treatment had significantly lower risk of
subsequent febrile malaria than children with 1 clone. We tested
the interaction term between number of clones and time of survey,
and confirmed that multiclonal infections act differently depending
on whether anti-malarial treatment had been given or not.
Children who were parasite negative at the cross-sectional surveys
had a lower risk of subsequent malaria in the following three
months periods irrespective of whether the child had received anti-
malarial treatment.
We analyzed the outcomes following clearance of asymptomatic
infection to distinguish lack of exposure from immunity, as
previously described [20]. Increasing clone number was associated
with increasing risk of subsequent exposure to parasites, and the
presence of 2 or more clones was associated with more blood stage
immunity (i.e. less febrile malaria compared with asymptomatic
infection). However, 0 clones (i.e. parasite negative), were also
strongly associated with more blood stage immunity. The
likelihood of being re-infected after clearance was not different
from that in children with parasites, suggesting that these children
experience similar levels of exposure. Being parasite negative and
able to control new infections without developing symptoms thus
suggests a rather efficient immunity, and ability to suppress
parasites below detection levels.
The present study provides with interesting insights into the
importance of multiclonal infections. Previous studies have shown
conflicting results, with the number of clones being related to risk
as well as to protection [13–15,25,26]. Although these differences
suggest an exposure dependent component, it has not been clear
whether the presence of the parasites per se are important or it they
just represent a marker of previous exposure. In two other areas in
Kilifi, infections with 2 clones were associated with an increased
risk of subsequent malaria in an area of low-moderate transmis-
sion, while in a low transmission village the diversity did not
predict the risk of clinical malaria [15]. Here, in this area of
moderate transmission, multiclonal infections were not associated
with disease risk, however when the asymptomatic infections were
cleared, the risk was reduced. This might indicate an immuno-
suppressive effect of persistent asymptomatic infection [27]; but
also that the multiclonal infections appear to have induced
immunity that protect against novel infections.
Several factors can affect the number of clones in an individual
at a certain time point [28]. The true number of genetically
distinct parasites in an infection is likely to be underestimated due
to within-host dynamics of circulating clones as well as
methodological limitations. The method used for genotyping is
well established in molecular epidemiological studies and the msp2
gene has proven to be the most informative marker of parasite
population diversity [29]. Moreover, fragment size determination
by capillary electrophoresis used here provide high resolution and
improved estimation of number and types of clones in an infection
compared to previous gel based methods [19].
The number of clones was associated with age, village of
residence and hemoglobin levels, however not with ITN use.
There was a substantial variance in the number of clones which
was not explained by age. The number of infecting clones at a
certain time point might reflect the individuals’ level of acquired
immunity as a result of previous exposure. Children with
asymptomatic, presumably chronic multiclonal infections, persist-
ing through the preceding low transmission season may have
mounted immune protection against super-infecting parasite
clones while children with previous single clone infections are
more susceptible when infected with novel parasite clones as the
transmission season starts.
Repeated clearance of asymptomatic parasitemias is the basis of
intermittent preventive treatment (IPT), a new strategy for malaria
control. Genotyping of P. falciparum infections after 6 months of
IPT given monthly or bimonthly to children in an area of high
seasonal transmission in Ghana resulted in a temporary reduction
of the number of clones and higher susceptibility compared to the
placebo group in which $2 clones conferred a reduced risk [30].
IPT strategies include repeated dosage and long half life drugs
with a prophylactic effect, e.g. sulphadoxine-pyrimethamine (SP)
or artesunate plus amodiaquine (AS+AQ). Here a short acting
drug, with no or negligible prophylactic effect, was used and thus
allowed for the assessment of clearance of parasites without
affecting exposure which could not be distinguished in the above
Table 3. Factors associated with re-infection, asymptomatic parasiteamia or clinical malaria during follow-up after anti-malarial
treatment.
Re-infected vs uninfected Clinical malaria vs asymptomatic infection
Odds ratio (95% CI) P Odds ratio (95% CI) P
msp2 clones 0 1.10 (0.55–2.19) 0.795 0.19 (0.05–0.73) 0.015
1* 1.0 1.0
$2 1.97 (0.99–3.93) 0.053 0.06 (0.02–0.25) ,0.001
Age 0.97 (0.84–1.13) 0.301 0.51 (0.37–0.71) 0.001
High transmission 2.23 (1.40–3.56) 0.001 0.14 (0.06–0.36) 0.056
ITN 0.59 (0.35–1.02) 0.058 0.42 (0.14–1.26) 0.122
*Reference group.
doi:10.1371/journal.pone.0016940.t003
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ties, both studies suggest that the exposure and persistence of
multiclonal infections are importance for maintenance of protec-
tive immunity.
Long periods of malaria chemoprophylaxis have been followed
by increased incidence of clinical malaria [31,32] as well as altered
cellular and humoral anti-parasitic immune responses [33,34]
suggesting impaired acquisition or maintenance of clinical
immunity. Antibody responses to P. falciparum are indeed more
long lived in the presence of asymptomatic infections [6] and have
been associated with a reduced risk of subsequent disease only in
parasite positive children in some studies [35,36].
In conclusion, a course of treatment of a short acting anti-
malarial drug affected the diversity of P. falciparum infections and
risk of subsequent clinical malaria. Why being infected with
multiple clones is only associated with protection following
clearance of parasites in this setting remains unclear. Possibly
the presence of parasites is partly immunosuppressive during some
stage of immune acquisition. However, multiclonal infections also
represent a marker of acquired immunity and memory. Under-
standing how immunity to multiclonal P. falciparum infections,
develops and how it is affected by different interventions will be
important in the development and evaluation of future strategies
for malaria control.
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